TARS

NEUTRAL

$65.97 Live

Tarsus Pharmaceuticals, Inc. · NASDAQ

Target $95.11 (+44.2%)

$38.51 52W Range $85.25

TARS Tarsus Pharmaceuticals, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

TARS Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$65.97

Analyst Target

$95.11

+44.2% Upside

52W High

$85.25

52W Low

$38.51

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026

Market cap

$2.81B

P/E

N/A

ROE

-23.4%

Profit margin

-14.7%

Debt/Equity

0.24

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

80%

TARS exhibits a critical Piotroski F-Score of 1/9, indicating severe weakness in current financial health and operational efficiency. However, this is contrasted by explosive YoY revenue growth of 128.40% and a strong gross margin of 78.95%, typical of a commercial-stage biotech scaling a first-in-class product (XDEMVY). While analysts maintain a 'strong_buy' rating with a target of $95.11, heavy insider selling by the CEO, CFO, and COO creates a significant divergence between institutional optimism and internal sentiment.

Key Strengths

Explosive revenue growth (128.40% YoY)

Strong gross margins (78.95%) indicating high product value

Excellent short-term liquidity (Current Ratio 3.85)

Low leverage (Debt/Equity 0.24)

First-mover advantage with FDA-approved XDEMVY for a large patient population

Key Risks

Critically low Piotroski F-Score (1/9) signaling poor financial health

Aggressive insider selling across the entire C-suite

Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

High valuation multiples (P/S 6.22, P/B 8.17) relative to current profitability

High dependence on a single primary product for revenue generation

AI Fair Value Estimate

Based on comprehensive analysis

$82.0

+24.3% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Growth

Key drivers: Revenue Hypergrowth, Poor Financial Health Score, Insider Divergence

Confidence

85%

Value

30/100

Trades at a significant premium to book value; valuation is driven by future growth expectations rather than current assets.

Positives

Forward P/E of 22.84 is reasonable for biotech growth

Watchpoints

High Price/Book (8.17)
High Price/Sales (6.22)
No Graham Number due to lack of earnings

Future

85/100

Growth metrics are top-tier, though earnings progression remains inconsistent.

Positives

128% Revenue growth
Target market of 25 million patients
First-in-class therapeutic status

Watchpoints

Earnings volatility
Execution risk in commercial scaling

Past

50/100

Strong product validation but poor financial forecasting accuracy.

Positives

Successful FDA approval and launch of XDEMVY
Strong 3Y and 5Y price appreciation

Watchpoints

Poor earnings surprise track record (-666.63% avg surprise last 4 quarters)

Health

20/100

While liquid, the company is fundamentally unhealthy from a deterministic accounting perspective (Piotroski).

Positives

Low Debt/Equity
High Current Ratio

Watchpoints

Piotroski F-Score of 1/9
Negative ROE and ROA

Dividend

0/100

Typical for growth-stage biotech; all capital is reinvested.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$65.97

Analyst Target

$95.11

Upside/Downside

+44.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TARS and closest competitors.

Updated 2026-04-20

Company	5Y	3Y	1Y	6M	1M	1W
TARS Tarsus Pharmaceuticals, Inc. Primary	+124.0%	+341.3%	+36.0%	-7.3%	+2.3%	-9.2%
ARQT Arcutis Biotherapeutics, Inc. Peer	-30.1%	+98.3%	+53.6%	+31.6%	-14.4%	-5.2%
SUPN Supernus Pharmaceuticals, Inc. Peer	+66.0%	+41.6%	+67.1%	+2.4%	+4.3%	+1.4%
HCM HUTCHMED (China) Limited Peer	-48.0%	-1.7%	+21.6%	+1.1%	+4.6%	-1.2%
LMAT LeMaitre Vascular, Inc. Peer	+140.7%	+121.7%	+42.2%	+33.8%	+6.0%	+5.7%

TAR

Tarsus Pharmaceuticals, Inc.

Primary

+124.0%

+341.3%

+36.0%

-7.3%

+2.3%

-9.2%

ARQ

Arcutis Biotherapeutics, Inc.

Peer

-30.1%

+98.3%

+53.6%

+31.6%

-14.4%

-5.2%

SUP

Supernus Pharmaceuticals, Inc.

Peer

+66.0%

+41.6%

+67.1%

+2.4%

+4.3%

+1.4%

HCM

HUTCHMED (China) Limited

Peer

-48.0%

-1.7%

+21.6%

+1.1%

+4.6%

-1.2%

LMA

LeMaitre Vascular, Inc.

Peer

+140.7%

+121.7%

+42.2%

+33.8%

+6.0%

+5.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

22.84

N/A

8.17

6.22

5.48

-35.77

$2.81B

Profitability

Profit margins and return metrics

Profit Margin -14.71%

Operating Margin -5.26%

Gross Margin 78.95%

ROE -23.39%

ROA -9.45%

Growth

Revenue and earnings growth rates

Revenue Growth +128.4%

Earnings Growth N/A

Q/Q Revenue Growth +128.39%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.24

Low debt

Current Ratio

3.85

Strong

Quick Ratio

3.72

Excellent

Cash/Share

$9.8

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.2B

Gross Margin

92.8%

Op. Margin

-5.3%

Net Margin

-5.5%

Total Assets

$0.6B

Liabilities

$0.2B

Equity

$0.3B

Debt/Equity

0.64x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

67%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-30

$N/A

2026-02-23

$-0.2

-1974.4% surprise

2025-11-04

$-0.3

+9.1% surprise

2025-08-06

$-0.48

-34.6% surprise

Healthcare Sector Comparison

Comparing TARS against 495 companies in the Healthcare sector (27 bullish, 152 neutral, 316 bearish)

Return on Equity (ROE)

-23.39%

This Stock

-95.69%

Sector Avg

-75.6% (Below Avg)

Profit Margin

-14.71%

This Stock

-15.8%

Sector Avg

-6.9% (Weaker)

Debt to Equity

0.24

This Stock

2.89

Sector Avg

-91.6% (Less Debt)

Revenue Growth

128.4%

This Stock

138.42%

Sector Avg

-7.2% (Slower)

Current Ratio

3.85

This Stock

4.66

Sector Avg

-17.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
TARS Tarsus Pharmaceuticals, Inc.	NEUTRAL	$2.81B	-	-23.4%	-14.7%	$65.97
ARQT Arcutis Biotherapeutics, Inc.	BEARISH	$2.82B	-	-9.3%	-4.3%	$22.75	Compare
SUPN Supernus Pharmaceuticals, Inc.	NEUTRAL	$2.96B	-	-3.7%	-5.4%	$51.39	Compare
HCM HUTCHMED (China) Limited	NEUTRAL	$2.62B	5.75	45.2%	83.3%	$15.24	Compare
LMAT LeMaitre Vascular, Inc.	NEUTRAL	$2.61B	45.48	15.8%	23.1%	$114.62	Compare

TARS Tarsus...

NEUTRAL

Mkt Cap

$2.8B

P/E

ROE

-23.4%

Price

$65.97

Compare with TARS

Compare with TARS

Compare with TARS

LMAT LeMaitre Vascular, Inc.

Compare with TARS

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-20	NEERVANNAN SESHADRI	Chief Operating Officer	Sale	2,989	$199,516
2026-03-19	FARROW JEFFREY S	Chief Financial Officer	Sale	6,430	$439,566
2026-03-19	MOTTIWALA AZIZ	Officer	Sale	13,056	$892,528
2026-03-19	NEERVANNAN SESHADRI	Chief Operating Officer	Sale	11,324	$772,444
2026-03-19	AZAMIAN BOBAK R	Chief Executive Officer	Sale	34,603	$2,364,904
2026-03-19	WHITFIELD DIANNE C	Officer	Sale	12,274	$839,070
2026-03-19	WAHL BRYAN	General Counsel	Sale	12,440	$850,417
2026-03-19	LIN ELIZABETH YEU	Officer	Sale	1,144	$78,204
2026-03-16	LINK WILLIAM J	Director	Sale	12,500	$859,819
2026-03-13	FARROW JEFFREY S	Chief Financial Officer	Stock Award	13,042	-
2026-03-13	MOTTIWALA AZIZ	Officer	Stock Award	26,482	-
2026-03-13	NEERVANNAN SESHADRI	Chief Operating Officer	Stock Award	26,287	-
2026-03-13	AZAMIAN BOBAK R	Chief Executive Officer	Stock Award	66,274	-
2026-03-13	WHITFIELD DIANNE C	Officer	Stock Award	23,909	-
2026-03-13	WAHL BRYAN	General Counsel	Stock Award	24,236	-

NEERVANNAN SESHADRI

Chief Operating Officer

Sell

2026-03-20

2,989 shares · $199,516

FARROW JEFFREY S

Chief Financial Officer

Sell

2026-03-19

6,430 shares · $439,566

MOTTIWALA AZIZ

Officer

Sell

2026-03-19

13,056 shares · $892,528

NEERVANNAN SESHADRI

Chief Operating Officer

Sell

2026-03-19

11,324 shares · $772,444

AZAMIAN BOBAK R

Chief Executive Officer

Sell

2026-03-19

34,603 shares · $2,364,904

WHITFIELD DIANNE C

Officer

Sell

2026-03-19

12,274 shares · $839,070

WAHL BRYAN

General Counsel

Sell

2026-03-19

12,440 shares · $850,417

LIN ELIZABETH YEU

Officer

Sell

2026-03-19

1,144 shares · $78,204

LINK WILLIAM J

Director

Sell

2026-03-16

12,500 shares · $859,819

FARROW JEFFREY S

Chief Financial Officer

Stock Award

2026-03-13

13,042 shares

MOTTIWALA AZIZ

Officer

Stock Award

2026-03-13

26,482 shares

NEERVANNAN SESHADRI

Chief Operating Officer

Stock Award

2026-03-13

26,287 shares

AZAMIAN BOBAK R

Chief Executive Officer

Stock Award

2026-03-13

66,274 shares

WHITFIELD DIANNE C

Officer

Stock Award

2026-03-13

23,909 shares

WAHL BRYAN

General Counsel

Stock Award

2026-03-13

24,236 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-02-23

TARS filed an 8-K on February 23, 2026, likely to announce its annual financial results.

10-K

2026-02-23

TARS is a commercial-stage biopharmaceutical company that launched XDEMVY in August 2023 for the treatment of Demodex blepharitis, targeting a potential U.S. patient population of 25 million. While specific financial metrics were not provided in the excerpts, the company cautions that actual results may vary materially from forward-looking projections due to inherent risks and uncertainties.

8-K

2026-02-18

TARS filed a current report on February 18, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-01-12

TARS filed a current report on January 12, 2026, to disclose material information to shareholders.

10-Q

2025-11-04

TARS filed its 10-Q on November 4, 2025, which includes a section on Risk Factors under Item 1A. Due to the limited information provided, specific financial highlights and detailed risk assessments are unavailable.

8-K

2025-11-04

10-Q

2025-08-06

TARS filed its quarterly 10-Q report on August 6, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for risk factors under Item 1A.

8-K

2025-08-06

TARS filed a current report on August 6, 2025, likely announcing its second-quarter financial results.

8-K

2025-06-18

TARS filed a current report on Form 8-K with the SEC on June 18, 2025, to disclose a material event.

10-Q

2025-05-01

8-K

2025-05-01

TARS filed a current report on May 1, 2025, likely announcing its first-quarter financial results.

DEF 14A

2025-04-28

8-K

2025-03-18

8-K

2025-03-13

10-K

2025-02-25

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

9 analysts

Oppenheimer

2026-02-25

Maintains

Outperform Outperform

Guggenheim

2026-02-25

Maintains

Buy Buy

Barclays

2025-12-09

init

Overweight

Mizuho

2025-11-20

init

Outperform

Guggenheim

2025-11-05

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning TARS from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

TARS

TARS Tarsus Pharmaceuticals, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!